Don't Let Congress Pass a Big Pharma Giveaway!
With all the news coming out of Washington, one issue affecting the future price of prescription drugs is not getting enough attention. Soon, a revised NAFTA trade deal, also known as the USMCA, will be considered in Congress.
Right now the deal includes a lot of provisions that would mean Americans paying even higher prices because it locks in rules that favor the powerful pharmaceutical corporations.
Congress can accept, reject or make changes to the agreement negotiated by the Trump Administration and the governments of Canada and Mexico. That means we need to act quickly to convince Congress to remove Big Pharma giveaways from NAFTA 2.0.
The USMCA deal locks in outrageously high U.S. drug prices and exports bad policies to Mexico and Canada, raising prices there as well. It will further delay the introduction of generic drugs into the markets.
Ambassador Jesus Seade, Mexico's Undersecretary for North America, admitted this recently. He told the media that the agreement would make it "more difficult to get generic" medicines.
Americans pay the highest prescription drug prices in the world, with one in five saying they can't afford their prescribed medication because of costs. We can't afford to enact a trade deal that would make things even worse.
We must convince Congress to remove the unfair pharmaceutical provisions from NAFTA 2.0. Please help us by adding your name to the petition which we will deliver to Congress soon.
Sign PetitionSign Petition
The revised NAFTA deal that Donald Trump signed would lock in high U.S. medicine prices. Big Pharma rigged the rules: NAFTA 2.0 guarantees extended monopoly rights for pharmaceutical corporations to block generic competition.
This would tie the hands of this and future Congresses to change the policies that lead to high drug prices. It also would export these bad policies to Mexico and Canada. We call on Congress to ensure that Donald Trump removes the Pharma giveaways from the revised NAFTA text before Congress begins consideration of the deal.